[HTML][HTML] A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor
T Yamamoto, C Lu, RO Ryan - Journal of biological chemistry, 2011 - ASBMB
PCSK9 (proprotein convertase subtilisin-like/kexin type 9) is an emerging target for
pharmaceutical intervention. This multidomain protein interacts with the LDL receptor
(LDLR), promoting receptor degradation. Insofar as PCSK9 inhibition induces a decrease in
plasma cholesterol levels, understanding the nature of the binding interaction between
PCSK9 and the LDLR is of critical importance. In this study, the ability of PCSK9 to compete
with apoE3 N-terminal domain-containing reconstituted HDL for receptor binding was …
pharmaceutical intervention. This multidomain protein interacts with the LDL receptor
(LDLR), promoting receptor degradation. Insofar as PCSK9 inhibition induces a decrease in
plasma cholesterol levels, understanding the nature of the binding interaction between
PCSK9 and the LDLR is of critical importance. In this study, the ability of PCSK9 to compete
with apoE3 N-terminal domain-containing reconstituted HDL for receptor binding was …